

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  44D0666807	<b>(X3) Date Survey Completed</b>  02/22/2022
<b>Name of Provider or Supplier</b>  Baptist Memorial Health Care	<b>Street Address, City, State</b>  7424 Hwy 64 Ste 111, Bartlett, TN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory participation in two out of three proficiency testing (PT) events for the White Blood Cell Differential analyte resulting in the first unsuccessful PT occurrence. (Refer to D2130)</p>
<b>D2130</b>	<p><b>HEMATOLOGY</b> CFR(s): 493.851(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.</p>

This STANDARD is not met as evidenced by:

Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and the laboratory's proficiency testing (PT) evaluation reports, the laboratory failed to maintain satisfactory performance in two out of three PT events for the White Blood Cell (WBC) Differential analyte in 2021. The findings include: 1. Review of the CMS 155 report revealed the following unsatisfactory WBC Differential analyte scores: 2021 Event one = 36% 2021 Event three = 28% 2. Review of the laboratory's 2021 PT hematology event one performance summary report revealed the following: Score of 0% for Basophils, 0% for Eosinophils, 80% for Lymphocytes, 100% for Monocytes, and 0% for Neutrophils, resulting in an overall score of 36% for the WBC Differential. 3. Review of the laboratory's 2021 PT hematology event three performance summary report revealed the following: Score of 0% for Basophils, 0% for Eosinophils, 60% for Lymphocytes, 80% for Monocytes, and 0% for Neutrophils, resulting in an overall score of 28% for the WBC Differential and the first unsuccessful PT occurrence for the WBC Differential.